1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Fresenius Delayed By FDA Inspection Uncertainty As It Works Towards US Pegfilgrastim Launch

Biosimilars Head Ali Ahmed Talks About Company’s Biosimilars Strategy

 
• By Akriti Seth

Ali Ahmed, senior vice president of biosimilars at Fresenius Kabi, considers the launch of the firm’s proposed Neulasta (pegfilgrastim) biosimilar in the US “an important milestone for the company.” However, he explains in an exclusive interview with Generics Bulletin, delays to necessary FDA inspections are creating uncertainty for the firm over launch timing.

Dealy
Ahmed said the upcoming pegfilgrastim launch was “an important milestone for the company” • Source: Fresenius Kabi

“Pegfilgrastim is not just another launch, this is our entry into the US biosimilars market,” stated Ali Ahmed, senior vice president of US biosimilars at Fresenius Kabi, talking about the company’s plan to launch its proposed Neulasta biosimilar in the US. In an exclusive interview, Ahmed told Generics Bulletin that “we engaged with a lot of key stakeholders and they're very excited for Fresenius Kabi to enter into the biosimilar market in the US.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Celltrion Celebrates Interchangeability Designation For Humira Biosimilar In The US

 
• By Urtė Fultinavičiūtė

Celltrion’s adalimumab biosimilar was crowned as interchangeable by the FDA, at a time when the future of the designation is unknown.

Samsung Bioepis Reevaluating Approach To Biosimilars

 
• By Jessica Merrill

The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.

Polpharma Looks To Supercharge Biosimilar Development With Help Of Chime

 
• By Dean Rudge

With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.

Cardinal Looks Ahead To A New Decade For US Biosimilars

 
• By Dave Wallace

In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.

More from Products

Samsung Bioepis Reevaluating Approach To Biosimilars

 
• By Jessica Merrill

The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.

Polpharma Looks To Supercharge Biosimilar Development With Help Of Chime

 
• By Dean Rudge

With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.

Cardinal Looks Ahead To A New Decade For US Biosimilars

 
• By Dave Wallace

In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.